New CRM launches
This article was originally published in The Gray Sheet
Boston Scientific announces CE-mark approval of the Cognis cardiac resynchronization therapy defibrillator (CRT-D) and the Teligent ICD Jan. 22. The company says the devices, for which a full rollout in international markets is planned in the second quarter, are among the smallest and thinnest implantable defibrillators available, at 32.5 cc and 31.5 cc, respectively. Both products are pending FDA approval, with a U.S. launch expected in the second half of 2008, the firm says (1"The Gray Sheet" Oct. 29, 2007, p. 16)
You may also be interested in...
Boston Scientific is highlighting recent and near-term product introductions as a key component of its plan to boost market share in its cardiac rhythm management business
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.
Russia is promising the best of both worlds – a low price with a near-perfect efficacy. While the basic science is plausible, its best-in-class claims are bound to generate skepticism.